NCIMMUNE LEADING EARLY CANCER DETECTION

Papers and publications written about Oncimmune and early cancer detection are listed below. Please click here for more information on our Scientific Advisory Board.

Date Title Link/PDF
October 29 Application of a High Throughput Method of Biomarker Discovery to Improvement of the EarlyCDT®-Lung Test PLOS ONE Application of a High Throughput Method of Biomarker Discovery to Improvement of the EarlyCDT®-Lung Test
October Autoantibodies to a panel of lung cancer-associated antigens can provide significant discrimination between malignant and non-malignant lung nodules World Congress for Lung Cancer (WCLC) in Sydney Meeting Poster Autoantibodies to a panel of lung cancer-associated antigens can provide significant discrimination between malignant and non-malignant lung nodules
October 14 Audit of the autoantibody test, EarlyCDT-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice Lung Cancer Audit of the autoantibody test, EarlyCDT-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice
September Autoantibody profiles in individuals with, and at risk for, Hepatocellular Carcinoma ILCA Annual Meeting Poster Autoantibody profiles in individuals with, and at risk for, Hepatocellular Carcinoma
September Changes in autoantibody profiles in individuals with, and at risk for, Hepatocellular Carcinoma ILCA Annual Meeting Poster Changes in autoantibody profiles in individuals with, and at risk for, Hepatocellular Carcinoma
August 23 Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer Journal of Thoracic Disease Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer
Date Title Link/PDF
November Challenges in Biomarker Development and Validation. In: Boyle P, Autier P, Adebamowo C, Anderson B, Pinillos Aston L, Badwe RA & Yamaguchi N. (Eds) World Breast Cancer Report 2012 Challenges in Biomarker Development and Validation. In: Boyle P, Autier P, Adebamowo C, Anderson B, Pinillos Aston L, Badwe RA & Yamaguchi N. (Eds)
October EarlyCDT-Lung Enhances the Positive Predictive Power of Computed Tomography for Detecting Lung Cancer CHEST 2012 Meeting EarlyCDT-Lung Enhances the Positive Predictive Power of Computed Tomography for Detecting Lung Cancer
October Benefits of Using EarlyCDT-Lung in Clinical Practice CHEST Annual Meeting Poster Benefits of Using EarlyCDT-Lung in Clinical Practice
October The Additive Effect of the Stratified EarlyCDT-Lung Serum Autoantibody Test on the Assessment of Lung Cancer Risk CHEST Annual Meeting Poster The Additive Effect of the Stratified EarlyCDT-Lung Serum Autoantibody Test on the Assessment of Lung Cancer Risk
September 6 An Audit of the Clinical Performance of EarlyCDT-Lung Chicago Multidisciplinary Symposium in Thoracic Oncology An Audit of the Clinical Performance of EarlyCDT-Lung
July 12 Development and Validation of a High Throughput System for Discovery of Antigens for Autoantibody Detection PLOS ONE Development and Validation of a High Throughput System for Discovery of Antigens for Autoantibody Detection
May 23 Signal Stratification of Autoantibody Levels In Serum Samples And Its Application To The Early Diagnosis of Lung Cancer ATS Annual Meeting Poster Signal Stratification of Autoantibody Levels In Serum Samples And Its Application To The Early Diagnosis of Lung Cancer
May Improved Specificity of the EarlyCDT-Lung Test Through Additional Autoantibody Assays ATS Annual Meeting Poster Improved Specificity of the EarlyCDT-Lung Test Through Additional Autoantibody Assays
May Poster Identification Of Tumor-Associated Autoantibodies To Different Forms Of Recombinant MAGE A4 ATS Annual Meeting Poster Poster Identification Of Tumor-Associated Autoantibodies To Different Forms Of Recombinant MAGE A4
March EarlyCDT-Lung test: improved clinical utility through additional autoantibody assays Tumor Biology EarlyCDT-Lung test: improved clinical utility through additional autoantibody assays
Date Title Link/PDF
December Serum autoantibodies to breast cancer associated antigens reflect tumour biology: an opportunity for early detection & prevention? SABCS 2011 Meeting Serum autoantibodies to breast cancer associated antigens reflect tumour biology: an opportunity for early detection & prevention?
October 31 Poster Autoantibodies as Immunobiomarkers in Lung Cancer and their use in Early Cancer Detection 7 AAb Panel Justification Poster Poster Autoantibodies as Immunobiomarkers in Lung Cancer and their use in Early Cancer Detection
October Autoantibodies in Ovarian Cancer ISOBM 2011 Meeting Autoantibodies in Ovarian Cancer
October Autoantibodies to p53 can Predate a Clinical Diagnosis of Ovarian Cancer - A Case Report ISOBM 2011 Meeting Autoantibodies to p53 can Predate a Clinical Diagnosis of Ovarian Cancer - A Case Report
July 7 EarlyCDT-Lung Test: Audit of the First 1000 Patients in Clinical Practice World Congress for Lung Cancer (WCLC) in Amsterdam Meeting Poster EarlyCDT-Lung Test: Audit of the First 1000 Patients in Clinical Practice
May 17 Cost-Effectiveness of Screening Older Adult Smokers for Lung Cancer with an Autoantibody Test (AABT) ATS Annual Meeting Poster Cost-Effectiveness of Screening Older Adult Smokers for Lung Cancer with an Autoantibody Test (AABT)
May 17 Demonstration Of The Specificity of Human Autoantibody Responses To Tumor-Associated Antigens ATS Annual Meeting Poster Demonstration Of The Specificity of Human Autoantibody Responses To Tumor-Associated Antigens
May 17 Identification of Tumor-Associated Autoantibodies in Mesothelioma ATS Annual Meeting Poster Identification of Tumor-Associated Autoantibodies in Mesothelioma
May 17 EarlyCDT-Lung – A Newly Marketed Blood Test To Aid The Early Detection Of Lung Cancer In High-Risk Patients – Enhances The Positive Predictive Power Of Computed Tomography ATS Annual Meeting Poster EarlyCDT-Lung – A Newly Marketed Blood Test To Aid The Early Detection Of Lung Cancer In High-Risk Patients – Enhances The Positive Predictive Power Of Computed Tomography
March 31 EarlyCDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung Cancer Cancer Prevention Research EarlyCDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung Cancer
Date Title Link/PDF
December An Improved EarlyCDT-Lung Test can be Used to Aid the Detection of Lung Cancer Chicago Multidisciplinary Symposium in Thoracic Oncology, An Improved EarlyCDT-Lung Test can be Used to Aid the Detection of Lung Cancer
November 30 Immuno-Biomarkers in Small Cell Lung Cancer: Potential Early Cancer Signals Clinical Cancer Research Immuno-Biomarkers in Small Cell Lung Cancer: Potential Early Cancer Signals
November 2 Reproducibility of Autoantibody Measurements in Normal Individuals Using the EarlyCDT-Lung Test CHEST Annual Meeting Poster Reproducibility of Autoantibody Measurements in Normal Individuals Using the EarlyCDT-Lung Test
November 2 An Autoantibody Test (AABT) to Aid in Early Detection of Lung Cancer in High-Risk Patients is Likely to be Cost-Effective CHEST Annual Meeting Poster An Autoantibody Test (AABT) to Aid in Early Detection of Lung Cancer in High-Risk Patients is Likely to be Cost-Effective
November 2 Stage 1a Non-Small Cell Lung Cancer Detected by Assaying Autoantibodies to Tumor Antigens CHEST Annual Meeting Poster Stage 1a Non-Small Cell Lung Cancer Detected by Assaying Autoantibodies to Tumor Antigens
November 2 EarlyCDT-Lung: QC measures reveal high precision, accuracy and robustness of a clinical test to aid in early lung cancer detection for high-risk individuals CHEST Annual Meeting Poster EarlyCDT-Lung: QC measures reveal high precision, accuracy and robustness of a clinical test to aid in early lung cancer detection for high-risk individuals
November 2 Poster Identification of Tumor-Associated Autoantibodies in Small Cell Lung Cancer as Immune Markers of Disease CHEST Annual Meeting Poster Poster Identification of Tumor-Associated Autoantibodies in Small Cell Lung Cancer as Immune Markers of Disease
September Does Heat Treatment of Human Serum Affect the Measurement of Autoantibodies to Recombinant Tumour-Associated Antigens? ISOBM 2010 Meeting Does Heat Treatment of Human Serum Affect the Measurement of Autoantibodies to Recombinant Tumour-Associated Antigens?
September The Presence of Autoantibodies to Tumour-Associated Antigens can Predate Clinical Diagnosis of Lung Cancer ISOBM 2010 Meeting The Presence of Autoantibodies to Tumour-Associated Antigens can Predate Clinical Diagnosis of Lung Cancer
July 30 Clinical validation of an autoantibody test for lung cancer Annals of Oncology Clinical validation of an autoantibody test for lung cancer
June Use of Serum Autoantibodies to Identify Early-Stage Lung Cancer: A Significant Step Forward in Early Detection ASCO Annual Meeting Abstracts Use of Serum Autoantibodies to Identify Early-Stage Lung Cancer: A Significant Step Forward in Early Detection
June Demographics of Populations at High Risk of Lung Cancer and Results of the EarlyCDT-Lung Test ASCO Annual Meeting Abstracts Demographics of Populations at High Risk of Lung Cancer and Results of the EarlyCDT-Lung Test
June Demographics of Populations at High Risk of Lung Cancer and Results of the EarlyCDT-Lung Test ASCO Annual Meeting General Poster Session Demographics of Populations at High Risk of Lung Cancer and Results of the EarlyCDT-Lung Test
June Use of serum autoantibodies to identify early-stage lung cancer ASCO Annual Meeting Abstracts Use of serum autoantibodies to identify early-stage lung cancer
June Reproducibility of autoantibody measurements in normal individuals using the EarlyCDT-Lung test ASCO Annual Meeting Abstracts Reproducibility of autoantibody measurements in normal individuals using the EarlyCDT-Lung test
June Cost-effectiveness of an autoantibody test (AABT) as an aid to diagnosis of lung cancer ASCO Annual Meeting Abstracts Cost-effectiveness of an autoantibody test (AABT) as an aid to diagnosis of lung cancer
May Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer PLOS ONE Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer
April Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer Lung Cancer Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer
February 2 Technical Validation of an autoantibody test for lung cancer Annals of Oncology Technical Validation of an autoantibody test for lung cancer

PLEASE READ THE FOLLOWING STATEMENT CAREFULLY

Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept